首页> 美国卫生研究院文献>Neuro-Oncology >RT-15IMPACT OF CHANGING TRENDS OF TREATMENT ON OUTCOME OF GLIOSARCOMA: A TERTIARY CARE CENTER EXPERIENCE
【2h】

RT-15IMPACT OF CHANGING TRENDS OF TREATMENT ON OUTCOME OF GLIOSARCOMA: A TERTIARY CARE CENTER EXPERIENCE

机译:RT-15治疗趋势的变化对胶质肉瘤结果的影响:三级护理中心的经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To assess the clinicopathological features and outcome in patients of primary gliosarcoma with changing trends of treatment. MATERIALS AND METHODS: Medical records were reviewed over a 5yearsperiod from 2009 to2013 of Gliosarcoma treated in the department. All patients who received 3D-Conformal Radiotherapy (3DCRT) with or without concurrent and adjuvant Temozolomide post surgery were included in the analysis. RESULTS: A total 27 patients were included in this study. Median age of presentation was 54 years (rang9-69 years), male to female ratio was 1.25:1, median KPS at presentation was 70. At presentation all patients had raised intracranial tension with motor symptoms in 48.1%, Memory impairment in 6 patients, Seizures and dimness of vision was seen in 18.5% and 11.1% cases respectively. Most common location of the tumour was temporal lobe (48.1%).About 60% (n = 16) patients underwent Gross total resection. On histopathological examination all patients showed biphasic pattern with glial fibrillary acidic protein positivity for (GFAP) glial component and vimentin positivity for mesenchymal component. Twenty three (80.8%) patients received radical radiotherapy i.e. 60 Gy/30#/6 weeks and 4 patients received hypo-fractionated radiotherapy 40 Gy in 15 fractions in 3 weeks. Eleven (42.3%) patients received Concurrent and adjuvant Temozolomide. Median overall survival of our patients was 9 months. Six months survival in the chemo-radiation arm was 82% as compared to 58% seen in patients who were treated with radiotherapy alone. CONCLUSION: Treating Gliosarcoma is a major therapeutic challenge to a clinician because of its poor prognosis, aggressive clinical behavior, rarity and limited clinical experience. Addition of Temozolomide has shown a better trend in survival though it is statistically not significant
机译:目的:通过改变治疗趋势来评估原发性胶质肉瘤患者的临床病理特征和预后。材料与方法:回顾性分析了从2009年至2013年在该科治疗的5年内的病历。分析包括所有接受3D适形放疗(3DCRT)的患者,术后接受或不接受并发替莫唑胺辅助治疗。结果:本研究共纳入27例患者。出现的中位年龄为54岁(9-69岁),男女之比为1.25:1,出现时的KPS中位数为70。出现时,所有患者的颅内压均升高,运动症状升高48.1%,记忆力减退6例,分别有18.5%和11.1%的病例出现癫痫发作和视力模糊。肿瘤最常见的部位是颞叶(48.1%)。约60%(n = 16)的患者接受了全切除。在组织病理学检查中,所有患者均表现为双相型,其中胶质纤维酸性蛋白对(GFAP)胶质成分呈阳性,波形蛋白对间质成分呈阳性。 23例(80.8%)患者接受了放射治疗,即60 Gy / 30#/ 6周,而4例患者则在3周内分15次进行了40 Gy的次分割放射治疗。 11例(42.3%)患者接受了同时和辅助的替莫唑胺治疗。我们患者的总体中位生存期为9个月。化学放射治疗组的六个月生存率为82%,而仅接受放射治疗的患者为58%。结论:治疗神经胶质肉瘤是临床医生面临的主要治疗挑战,因为其预后差,侵略性临床行为,稀有性和有限的临床经验。尽管在统计学上不显着,但添加替莫唑胺显示出更好的生存趋势

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号